Big pharma might cut research, delay new drugs if pharmacare means more generics: memo
Sunday, April 14, 2019 - 11:30
in Mathematics & Economics
Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national pharmacare plan, according to an internal federal analysis.